| Similar Articles |
|---|
 |
Chemistry World
June 16, 2014
Phillip Broadwith |
Novo Nordisk to create 6000 jobs by 2022 Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D.   |
Chemistry World
September 24, 2012
Andrew Turley |
$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs. |
The Motley Fool
February 28, 2005
Salim Haji |
Why Value Trumps Growth Growth vs. value: This author works it out and comes up with a definitive answer. Obviously, the best possible investment is a combination -- buying a growth stock at a discount to intrinsic value. |
The Motley Fool
August 22, 2005
Richard Gibbons |
Putting a Price on Tomorrow's Dollar Here's one way to calculate the value of any stock. |
The Motley Fool
February 13, 2008
Todd Wenning |
The Safest Places to Invest If you are thinking to invest internationally, but you are risk-adverse, take a look at this list of the five countries with the lowest operational risk and notable stocks headquartered in each. |
The Motley Fool
December 27, 2005 |
Foolish Fundamentals: Valuation Here's one way to calculate the value of any stock. |
The Motley Fool
September 20, 2006
Tim Beyers |
What Is Valuation? Though it may sometimes seem like it, stock prices aren't random. And the best investors know it. So how do investors decide whether or not a stock is a "buy"? Valuation. |
The Motley Fool
June 18, 2010
Jim Mueller |
So What's a Fair Value for Apple? After reading about Apple all week, the big question remains. What's a fair price for the whole thing? |
The Motley Fool
November 29, 2005
Shannon Zimmerman |
Can FedEx Deliver? Is this transportation giant's price right? Investors, take note. |
The Motley Fool
August 12, 2005
Stephen D. Simpson |
Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market. |
CFO
November 1, 2010
Janet Kersnar |
Finance as a First-Mover, Literally Novo Nordisk's offshoring effort pays dividends. |
The Motley Fool
March 28, 2007
Anders Bylund |
Finding True Value: Discounted Cash Flows Finally, we find a valuation model that suits complex businesses like Texas Instruments. |
Financial Planning
May 1, 2005
Glenn G. Kautt |
What Are You Worth? Regarding owners of investment advisory firms, for sellers, it's back to the future, but for buyers, it's here and now. |
The Motley Fool
January 28, 2005
Stephen D. Simpson |
An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk. |
The Motley Fool
May 11, 2005
Jim Schoettler |
Digging Into Buffett's Numbers Here's a detailed example of the Discounted Cash Flow (DCF) valuation model, and the specific assumptions Warren Buffett uses when applying the DCF model to investment opportunities. |
The Motley Fool
April 29, 2005
Chris Mallon |
Market Contractions: Ouch! Accelerating inflation and rising interest rates are prepared to wreak havoc on growth stocks. |
The Motley Fool
May 10, 2005
Jim Schoettler |
Buffett by Numbers Want to invest like Buffett? We derive the method Buffett uses to analyze the quantitative worth of a company. |
The Motley Fool
October 31, 2006
Brian Lawler |
Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note. |
The Motley Fool
August 23, 2007
Sham Gad |
Security Analysis 401: Calculating Intrinsic Value Investors, calculating intrinsic value is simple and straightforward. It's having accurate data that's the difficult part. |
The Motley Fool
February 4, 2008
Brian Lawler |
Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers. |
The Motley Fool
October 31, 2008
Brian Orelli |
Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales.. |
The Motley Fool
January 31, 2007
Brian Lawler |
Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment. |
